Monday, February 2, 2009
The end of axitinib
Pfizer was developing axitinib (a tyrosine kinase inhibitor or TKI) for the treatment of pancreatic cancer. Unfortunately, recent Phase III results were disappointing. As a result, Pfizer has terminated development on this agent. This is just another failure example of all the money, time, and energy spent on drug development research. It really is a shame because we need more effective therapies in oncology.